RESPeCT: Revlimid Early Stage Poor prognosis CLL Trial

• Research type

  Research Study

• Full title

  A single arm phase II study to investigate the use of Lenalidomide in the treatment of patients with early stage CLL associated with poor prognostic factors.

• IRAS ID

  16233

• Contact name

  Adrian Bloor

• Contact email

  adrian.bloor@christie.nhs.uk

• Sponsor organisation

  The Christie NHS Foundation Trust

• Eudract number

  2009-011078-14

• Research summary

  Research Summary not published at request of researcher

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  09/H1008/122

• Date of REC Opinion

  27 Nov 2009

• REC opinion

  Further Information Favourable Opinion